| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C10H10F3NO2S |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
PXS-6302 is an irreversible lysyl oxidase inhibitor, with IC50 values of 3.7 μM against bovine LOX, 3.4 μM against recombinant human LOXL1, 0.4 μM against recombinant human LOXL2, 1.5 μM against recombinant human LOXL3, and 0.3 μM against recombinant human LOXL4. It readily penetrates skin, reduces collagen deposition, and significantly improves scar appearance[1]. Its molecular formula is C10H10F3NO2S, with a molecular weight of 265.25 g/mol.
Physical & Chemical Properties
| CAS Number | 2584947-54-4 |
|---|---|
| Molecular Formula | C10H10F3NO2S |
| Molecular Weight | 265.25 g/mol |
| SMILES | NC/C=C(C(F)(S(=O)(C1=CC=CC=C1)=O)F)\F |
| Signaling Pathway | Neuronal Signaling |
| Solubility | In Vitro: DMSO: 100 mg/mL (377.00 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
Activity & Target
3.7 μM (Bovine LOX), 3.4 μM (rh LOXL1), 0.4 μM (rh LOXL2), 1.5 μM (rh LOXL3), 0.3 μM (rh LOXL4)[1]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (377.00 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | 2.5 mg/mL (9.43 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 2.5 mg/mL. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | 2.5 mg/mL (9.43 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 2.5 mg/mL. Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
PXS-6302 shows high permeability across a monolayer of cells, such as Caco-2 or MDCKII cells[1].
In Vivo
In porcine models of excisional and burn injury, PXS-6302 inhibits LOX, reduces crosslinking, and improves scar appearance[1]. Topical PXS-6302 (1.5% oil in water cream) applied externally once daily for 28 days, at 500 mg cream per 16 cm2, reduces collagen deposition and cross-linking in murine models of injury and fibrosis[1]. Topical PXS-6302 (0.5, 1.5, or 3% oil in water cream) applied externally at 400 mg cream per 16 cm2 once daily for 12 weeks also significantly improves scar appearance in porcine injury models, without reducing tissue strength[1].
| Animal Model | Porcine excision injury model (female Juvenile pigs, 18-20 kg)[1] |
|---|---|
| Dosage | 0.5, 1.5, or 3%, oil in water cream; 400 mg cream applied to 16 cm2 |
| Administration | External application; 1, 2 and 3 weeks post-injury; once dayly, for 12 weeks |
| Result | Showed significantly higher scores for the 3% treated scars suggesting significant improvement in scar appearance. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
